CRVO CervoMed Inc.
Company Analysis
Latest News
CervoMed to Present Initial Neflamapimod Phase 2a Trial Data at ISFTD 2026 Conference
CervoMed (CRVO) announced that initial results from its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive aphasia (nfvPPA), a...
🔴 CervoMed is trading 5% down today as broader U.S. equities weakened
CervoMed is trading 5.17% down now at $2.57 after broader U.S. equities weakened on August 20, 2026. - The S&P 500, Nasdaq Composite, and Dow Jones were all...
🟢 CervoMed is trading 5.2% up in after-hours trading as healthcare sector rallies
CervoMed is trading 5.15% up now at $2.85 after the broader healthcare sector rallied. - XLV reportedly gained 3.2% on stronger earnings expectations and...
🟢 CervoMed rises 5.8% — Healthcare Stocks Surge on Strong Earnings Outlook and Investor Rotation
With Healthcare (XLV) up 3.2%, this looks like a sector-led move rather than a company-specific surprise. The healthcare sector experienced a significant...
🔴 CervoMed is trading 5% down today with no clear catalyst identified
CervoMed is trading at $2.59, down -5.13%, with no clear company-specific catalyst identified for August 17, 2026. - No new August 17 announcement, earnings...
🟢 CervoMed is trading 5.4% up in pre-market
CervoMed is trading 5.4% up in pre-market at $2.88, rebounding from its August 14 close of $2.73; no new company-specific catalyst was identified. - No new...
🔴 CervoMed is trading 5.87% down today
CervoMed is trading 5.87% down at $2.76, continuing weakness after declining 4.56% to $2.93 on August 13, 2026. - No new company-specific announcement dated...
🟢 CervoMed is trading 6.3% up today in pre-market after flat July PPI reduced Fed hike expectations
CervoMed is trading at $3.11, +6.28% now, as flat July PPI data reduced expectations for a September Federal Reserve rate hike. • Broader risk appetite...
🟢 CervoMed is trading 7.34% up today in after-hours trading as flat July PPI supported rate-hold expectations
CervoMed is trading at $3.15 (+7.34%) in after-hours trading as broader markets strengthened after July PPI was flat, supporting expectations that the Federal...
CervoMed Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 14, 2026
For the second quarter of 2026, analysts anticipate a consensus revenue of $0.05 million and an EPS of -$0.87, while the current price of $2.86 sits...
🟢 CervoMed is trading 11.19% up today after $20.5 million financing extends cash runway
CervoMed is trading 11.19% up at $3.18 after its August 10, 2026 earnings highlighted a $6.6 million quarterly loss and extended cash runway into late 2027...
CervoMed's second quarter 2026 net loss hits $6.6M as cash runway extends into 2027
CervoMed reported a net loss of $6.6 million for the second quarter of 2026, primarily reflecting the transition of its lead candidate neflamapimod toward...
CervoMed Posts Q2 Results and Banks on a Partner to Reach the Finish Line — But Will Anyone Bite?
Shares of CervoMed jumped 7.3% to $3.07 after the clinical-stage biotech reported second-quarter 2026 results that gave investors what they most needed: more...
🟢 CervoMed is trading 7.3% up in after-hours trading after extending cash runway through Q3 2027
CervoMed is trading at $3.07 (+7.34%) after reporting second-quarter 2026 results and corporate updates. • Cash runway extends through Q3 2027, supported by...
🔴 CervoMed is trading 5.2% down today with no confirmed catalyst identified
CervoMed is trading at $2.72, down 5.23%, with no confirmed catalyst identified. - No new company-specific announcement dated August 7–10 was identified; the...
🟢 CervoMed is trading 5% up today after neflamapimod’s UK Innovation Passport designation
CervoMed is trading 5.34% up now at $2.96 after neflamapimod received an Innovation Passport designation under the UK’s Innovative Licensing and Access Pathway...
CervoMed's Neflamapimod Granted UK Innovation Passport for Dementia with Lewy Bodies
CervoMed Inc. announced that its lead drug candidate, neflamapimod, has been awarded an Innovation Passport designation in the United Kingdom. This designation...
🟢 CervoMed is trading 5.8% up today amid a broader market rally
CervoMed is trading at $2.75 (5.8% up), extending its recent rebound from late-July lows amid a broader risk-on market environment. • The upward move appears...
🔴 CervoMed is trading 6.4% down today amid broader small-cap biotech volatility
CervoMed is trading at $2.49, down 6.4% today, amid a lack of fresh company-specific news or filings to explain the downward move. • The decline follows a...
🟢 CervoMed is trading 5.3% up today amid a broader market rebound
CervoMed is trading 5.3% higher at $2.80 in pre-market action, likely tracking a broader market rebound as major indices rise. • The stock is up from its...